NASDAQ:SBBP

Strongbridge Biopharma Competitors

$2.47
-0.16 (-6.08 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.45
Now: $2.47
$2.65
50-Day Range
$2.61
MA: $2.97
$3.62
52-Week Range
$1.86
Now: $2.47
$4.63
Volume1.06 million shs
Average Volume1.09 million shs
Market Capitalization$166.84 million
P/E RatioN/A
Dividend YieldN/A
Beta1.91

Competitors

Strongbridge Biopharma (NASDAQ:SBBP) Vs. CLVS, OGI, GOSS, KDMN, EVLO, and XENE

Should you be buying SBBP stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Strongbridge Biopharma, including Clovis Oncology (CLVS), OrganiGram (OGI), Gossamer Bio (GOSS), Kadmon (KDMN), Evelo Biosciences (EVLO), and Xenon Pharmaceuticals (XENE).

Strongbridge Biopharma (NASDAQ:SBBP) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares Strongbridge Biopharma and Clovis Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Strongbridge Biopharma-149.79%-65.85%-38.81%
Clovis Oncology-230.34%N/A-57.56%

Analyst Recommendations

This is a summary of recent ratings and price targets for Strongbridge Biopharma and Clovis Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Strongbridge Biopharma00303.00
Clovis Oncology22202.00

Strongbridge Biopharma currently has a consensus target price of $7.00, suggesting a potential upside of 183.40%. Clovis Oncology has a consensus target price of $9.50, suggesting a potential upside of 54.22%. Given Strongbridge Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Strongbridge Biopharma is more favorable than Clovis Oncology.

Valuation and Earnings

This table compares Strongbridge Biopharma and Clovis Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Strongbridge Biopharma$21.71 million7.68$-49,450,000.00($1.10)-2.25
Clovis Oncology$143.01 million4.50$-400,420,000.00($7.60)-0.81

Strongbridge Biopharma has higher earnings, but lower revenue than Clovis Oncology. Strongbridge Biopharma is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Strongbridge Biopharma has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.

Institutional & Insider Ownership

58.3% of Strongbridge Biopharma shares are owned by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are owned by institutional investors. 6.6% of Strongbridge Biopharma shares are owned by company insiders. Comparatively, 6.6% of Clovis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Strongbridge Biopharma beats Clovis Oncology on 9 of the 13 factors compared between the two stocks.

OrganiGram (NASDAQ:OGI) and Strongbridge Biopharma (NASDAQ:SBBP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and price targets for OrganiGram and Strongbridge Biopharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrganiGram07402.36
Strongbridge Biopharma00303.00

OrganiGram currently has a consensus price target of $4.5988, suggesting a potential upside of 66.02%. Strongbridge Biopharma has a consensus price target of $7.00, suggesting a potential upside of 183.40%. Given Strongbridge Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Strongbridge Biopharma is more favorable than OrganiGram.

Risk and Volatility

OrganiGram has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Strongbridge Biopharma has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500.

Insider & Institutional Ownership

10.8% of OrganiGram shares are owned by institutional investors. Comparatively, 58.3% of Strongbridge Biopharma shares are owned by institutional investors. 6.6% of Strongbridge Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares OrganiGram and Strongbridge Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganiGram-207.26%-10.00%-7.14%
Strongbridge Biopharma-149.79%-65.85%-38.81%

Valuation & Earnings

This table compares OrganiGram and Strongbridge Biopharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrganiGram$64.61 million9.96$-101,290,000.00($0.08)-34.63
Strongbridge Biopharma$21.71 million7.68$-49,450,000.00($1.10)-2.25

Strongbridge Biopharma has lower revenue, but higher earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Strongbridge Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Strongbridge Biopharma beats OrganiGram on 8 of the 14 factors compared between the two stocks.

Gossamer Bio (NASDAQ:GOSS) and Strongbridge Biopharma (NASDAQ:SBBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Institutional and Insider Ownership

72.0% of Gossamer Bio shares are owned by institutional investors. Comparatively, 58.3% of Strongbridge Biopharma shares are owned by institutional investors. 23.3% of Gossamer Bio shares are owned by company insiders. Comparatively, 6.6% of Strongbridge Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Gossamer Bio and Strongbridge Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gossamer Bio00503.00
Strongbridge Biopharma00303.00

Gossamer Bio currently has a consensus target price of $23.00, indicating a potential upside of 173.16%. Strongbridge Biopharma has a consensus target price of $7.00, indicating a potential upside of 183.40%. Given Strongbridge Biopharma's higher possible upside, analysts clearly believe Strongbridge Biopharma is more favorable than Gossamer Bio.

Profitability

This table compares Gossamer Bio and Strongbridge Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gossamer BioN/A-64.34%-46.52%
Strongbridge Biopharma-149.79%-65.85%-38.81%

Valuation & Earnings

This table compares Gossamer Bio and Strongbridge Biopharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.56
Strongbridge Biopharma$21.71 million7.68$-49,450,000.00($1.10)-2.25

Strongbridge Biopharma has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Strongbridge Biopharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gossamer Bio has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Strongbridge Biopharma has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500.

Strongbridge Biopharma (NASDAQ:SBBP) and Kadmon (NASDAQ:KDMN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares Strongbridge Biopharma and Kadmon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Strongbridge Biopharma-149.79%-65.85%-38.81%
Kadmon-768.36%-85.07%-46.46%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Strongbridge Biopharma and Kadmon, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Strongbridge Biopharma00303.00
Kadmon00503.00

Strongbridge Biopharma currently has a consensus target price of $7.00, indicating a potential upside of 183.40%. Kadmon has a consensus target price of $12.75, indicating a potential upside of 246.47%. Given Kadmon's higher probable upside, analysts clearly believe Kadmon is more favorable than Strongbridge Biopharma.

Risk & Volatility

Strongbridge Biopharma has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Kadmon has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of Strongbridge Biopharma shares are owned by institutional investors. Comparatively, 94.8% of Kadmon shares are owned by institutional investors. 6.6% of Strongbridge Biopharma shares are owned by company insiders. Comparatively, 3.0% of Kadmon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Strongbridge Biopharma and Kadmon's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Strongbridge Biopharma$21.71 million7.68$-49,450,000.00($1.10)-2.25
Kadmon$5.09 million124.22$-61,370,000.00($0.74)-4.97

Strongbridge Biopharma has higher revenue and earnings than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than Strongbridge Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Strongbridge Biopharma beats Kadmon on 8 of the 13 factors compared between the two stocks.

Evelo Biosciences (NASDAQ:EVLO) and Strongbridge Biopharma (NASDAQ:SBBP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Ratings

This is a summary of recent ratings for Evelo Biosciences and Strongbridge Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evelo Biosciences02302.60
Strongbridge Biopharma00303.00

Evelo Biosciences currently has a consensus price target of $20.00, indicating a potential upside of 69.20%. Strongbridge Biopharma has a consensus price target of $7.00, indicating a potential upside of 183.40%. Given Strongbridge Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Strongbridge Biopharma is more favorable than Evelo Biosciences.

Institutional and Insider Ownership

84.6% of Evelo Biosciences shares are held by institutional investors. Comparatively, 58.3% of Strongbridge Biopharma shares are held by institutional investors. 7.3% of Evelo Biosciences shares are held by company insiders. Comparatively, 6.6% of Strongbridge Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Evelo Biosciences and Strongbridge Biopharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A$-85,470,000.00($2.67)-4.43
Strongbridge Biopharma$21.71 million7.68$-49,450,000.00($1.10)-2.25

Strongbridge Biopharma has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Strongbridge Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evelo Biosciences and Strongbridge Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evelo BiosciencesN/A-159.17%-88.81%
Strongbridge Biopharma-149.79%-65.85%-38.81%

Volatility & Risk

Evelo Biosciences has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Strongbridge Biopharma has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500.

Summary

Strongbridge Biopharma beats Evelo Biosciences on 9 of the 12 factors compared between the two stocks.

Xenon Pharmaceuticals (NASDAQ:XENE) and Strongbridge Biopharma (NASDAQ:SBBP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Institutional & Insider Ownership

79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.3% of Strongbridge Biopharma shares are owned by institutional investors. 8.4% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 6.6% of Strongbridge Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Xenon Pharmaceuticals and Strongbridge Biopharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xenon Pharmaceuticals00503.00
Strongbridge Biopharma00303.00

Xenon Pharmaceuticals currently has a consensus price target of $25.25, suggesting a potential upside of 44.04%. Strongbridge Biopharma has a consensus price target of $7.00, suggesting a potential upside of 183.40%. Given Strongbridge Biopharma's higher probable upside, analysts plainly believe Strongbridge Biopharma is more favorable than Xenon Pharmaceuticals.

Valuation & Earnings

This table compares Xenon Pharmaceuticals and Strongbridge Biopharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xenon Pharmaceuticals$6.83 million91.91$-41,600,000.00($1.54)-11.38
Strongbridge Biopharma$21.71 million7.68$-49,450,000.00($1.10)-2.25

Xenon Pharmaceuticals has higher earnings, but lower revenue than Strongbridge Biopharma. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Strongbridge Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Xenon Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Strongbridge Biopharma has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500.

Profitability

This table compares Xenon Pharmaceuticals and Strongbridge Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xenon Pharmaceuticals-102.25%-21.76%-16.08%
Strongbridge Biopharma-149.79%-65.85%-38.81%

Summary

Xenon Pharmaceuticals beats Strongbridge Biopharma on 8 of the 13 factors compared between the two stocks.


Strongbridge Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.16-1.1%$643.91 million$143.01 million-1.18
OrganiGram logo
OGI
OrganiGram
1.6$2.77-10.1%$643.39 million$64.61 million-4.07Decrease in Short Interest
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.42-3.8%$635.95 millionN/A-2.37Increase in Short Interest
Kadmon logo
KDMN
Kadmon
1.8$3.68-0.5%$632.29 million$5.09 million-6.13
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$11.82-15.1%$630.42 millionN/A-4.75Analyst Upgrade
News Coverage
Gap Down
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.53-0.5%$627.73 million$6.83 million-18.07
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$27.00-5.1%$623.43 million$13.80 million-13.04
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$25.23-3.6%$613.29 million$12.69 million-12.13Increase in Short Interest
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$31.94-2.9%$610.50 million$9.64 million-5.20
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.67-1.2%$597.37 millionN/A-16.51
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$13.60-9.0%$576.33 million$17.26 million-3.78Earnings Announcement
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.80-4.4%$572.96 millionN/A-6.05
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$17.76-11.8%$572.94 millionN/A-9.45
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.11-0.2%$565.13 million$1.19 million-7.13
Evolus logo
EOLS
Evolus
1.1$12.72-6.8%$556.28 million$34.92 million-6.27
Inventiva logo
IVA
Inventiva
0.0$14.35-0.6%$554.34 millionN/A0.00
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.71-2.8%$553.26 millionN/A-9.08Increase in Short Interest
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.18-0.1%$553.04 millionN/A-5.28News Coverage
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.15-3.6%$551.43 million$8 million-7.44News Coverage
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.32-0.6%$546.13 million$195.89 million118.06
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.08-0.3%$543.38 million$26.74 million17.70
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.09-5.5%$525.67 million$59.29 million-20.60Increase in Short Interest
Provention Bio logo
PRVB
Provention Bio
1.6$8.23-2.8%$521.58 millionN/A-5.52Analyst Report
Increase in Short Interest
News Coverage
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.48-0.7%$520.09 million$36.63 million-6.45News Coverage
Gap Down
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.28-3.1%$514.63 million$49.65 million-1.80
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.15-1.5%$514.26 million$25 million-18.69Analyst Report
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.69-3.2%$513.07 millionN/A-4.52
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$13.99-10.9%$511.73 millionN/A-4.03News Coverage
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.29-3.7%$504.53 millionN/A-7.99News Coverage
Akouos logo
AKUS
Akouos
1.6$14.51-4.4%$499.17 millionN/A0.00
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.86-1.0%$497.08 million$58.12 million-16.11Decrease in Short Interest
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.44-4.0%$493.45 million$59.22 million42.20
XBiotech logo
XBIT
XBiotech
1.0$16.75-1.2%$493.44 millionN/A1.16
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.38-1.8%$485.50 millionN/A-2.55
AC Immune logo
ACIU
AC Immune
1.3$6.62-3.8%$476.22 million$111.75 million-7.36
89bio logo
ETNB
89bio
1.6$23.80-10.4%$474.72 millionN/A-4.71
Altimmune logo
ALT
Altimmune
1.9$12.57-2.6%$466.98 million$5.80 million-6.32Increase in Short Interest
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$33.91-17.0%$458.09 million$40,000.00-1.47High Trading Volume
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$2.98-2.7%$457.44 million$335 million-1.01
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.48-2.7%$454.38 million$56.50 million0.00
Geron logo
GERN
Geron
1.4$1.42-4.2%$452.31 million$460,000.00-4.06Decrease in Short Interest
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.94-4.4%$451.96 million$109.33 million-2.16Analyst Report
News Coverage
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$12.14-1.2%$446.96 millionN/A0.00
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.29-0.9%$445.41 million$102.31 million6.40Increase in Short Interest
Verastem logo
VSTM
Verastem
1.3$2.57-7.4%$441.18 million$17.46 million-1.82Analyst Revision
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.75-1.4%$439.95 millionN/A0.00Gap Down
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.82-5.2%$438.33 million$22.27 million-3.83
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$6.74-14.5%$436.64 million$57.49 million-5.66Increase in Short Interest
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.86-1.0%$434.05 millionN/A-11.95
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.